De Novo Classification Request

The De Novo pathway is designed for devices with no legally marketed predicate in the United States. Unlike a 510(k) submission, which requires demonstrating Substantial Equivalence to an existing device, the De Novo process creates an entirely new classification regulation. This is the appropriate route when a device's intended use or technological characteristics are genuinely novel and the device presents a low to moderate risk profile that can be mitigated by general controls or general and special controls.

When the FDA grants a De Novo request and classifies a device into Class II, the agency simultaneously establishes special controls unique to that device type. These controls are legally binding requirements that may include:

• Performance testing benchmarks and standards
• Post-market surveillance protocols
• Patient registries for long-term data collection
• Labeling requirements specific to the technology These special controls, combined with general controls, provide reasonable assurance of safety and effectiveness.

A successful De Novo classification has a cascading regulatory effect. Once the FDA classifies the device and publishes the new regulation, that device becomes a legally marketed predicate for subsequent 510(k) submissions. This means:

• Competitors can use the De Novo device as a predicate
• The original submitter gains first-mover advantage in defining the regulatory category
• The new classification establishes the standard of evidence for the device type This mechanism incentivizes innovation while building a structured regulatory framework over time.

There are two distinct paths to a De Novo classification:

Direct De Novo: The submitter files a De Novo request directly with the FDA without first submitting a 510(k). This is appropriate when the submitter knows the device has no predicate.

Reclassification De Novo: The submitter first files a 510(k) and receives a Not Substantially Equivalent (NSE) determination. Within 30 days, they may submit a De Novo request to reclassify the device. This path is common when predicate uncertainty exists during initial regulatory strategy.

A De Novo request must provide a comprehensive demonstration of reasonable assurance of safety and effectiveness. Key submission elements include:

• Device description and principle of operation
• Intended Use and Indications for Use statements
• Summary of non-clinical testing (bench, engineering, biocompatibility)
• Clinical data when necessary to establish safety and effectiveness
• Risk analysis per ISO 14971
• Proposed classification recommendation with rationale
• Benefit-risk analysis demonstrating probable benefits outweigh probable risks The evidentiary burden is higher than a 510(k) but lower than a Premarket Approval (PMA).

The FDA has a statutory review clock of 120 days for De Novo requests, though the actual timeline may extend if the agency issues an Additional Information (AI) request. Key milestones include:

• Acceptance Review: FDA confirms the submission is administratively complete (15 days)
• Substantive Review: In-depth scientific and clinical evaluation
• Interactive Review: FDA may request clarifications or additional data
• Final Decision: Grant (with classification regulation) or Decline Upon granting, the FDA publishes a Federal Register notice announcing the new classification and special controls, making the decision public and precedential.

A determination that a new device is as safe and effective as a predicate device. This is the foundational concept of the 510(k) pathway and the precise determination that a De Novo request explicitly does not require.

• Comparison Points: Intended use, technological characteristics, performance data
• De Novo Distinction: A De Novo request is submitted precisely because substantial equivalence cannot be established due to the absence of a predicate
• Regulatory Implication: Once a device is cleared via De Novo, it can serve as a predicate for future 510(k) submissions

The systematic and planned process to continuously generate, collect, analyze, and assess clinical data pertaining to a medical device to verify its safety and performance. For De Novo submissions, clinical evaluation data is essential to demonstrate reasonable assurance of safety and effectiveness.

• Data Sources: Clinical investigations, scientific literature, post-market surveillance data
• De Novo Requirement: Must demonstrate that the benefits outweigh the risks for the novel intended use
• Ongoing Obligation: Clinical evaluation continues throughout the device lifecycle as part of post-market surveillance